ArticleCancer discovery2015
MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.
Article in Cancer discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Review
- Review
- Targeting the hedgehog pathway in MET mutation cancers and its effects on cells associated with cancer development.Cell communication and signaling : CCS · 2023Review
- NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease.International journal of molecular sciences · 2022Review
- Has programmed cell death ligand-1Translational lung cancer research · 2021Review
- MET Exon 14 Skipping: A Case Study for the Detection of Genetic Variants in Cancer Driver Genes by Deep Learning.International journal of molecular sciences · 2021Article
- Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma HarboringOncoTargets and therapy · 2021Article
- Review
- The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET.American journal of cancer research · 2020Article
- Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.Journal of hematology & oncology · 2019Review
- Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.Cancer research and treatment · 2019Article
- MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.Journal of hematology & oncology · 2019Review
- Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis.EMBO molecular medicine · 2019Article
- (Not Giving Up) The Marathon Race of MET Targeting Therapy: Are We There Yet?Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.British journal of cancer · 2019Article
- Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non-Small Cell Lung Cancer.The Journal of molecular diagnostics : JMD · 2019Article
- Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer.Biomarker research · 2019Review
- Special issue: "MET as actionable target in cancer therapy".Annals of translational medicine · 2017Article
- MET/HGF pathway activation as a paradigm of resistance to targeted therapies.Annals of translational medicine · 2017Review
- Effective implementation of novel MET pharmacodynamic assays in translational studies.Annals of translational medicine · 2017Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author.
Funding
Abstract
Clinical studies on MET-targeting cancer therapeutics have yielded mixed results in recent years, and MET-relevant predictive biomarkers remain elusive. New studies now reveal METex14 alternative splicing aberrations to represent potential predictive cancer genomic biomarker, hence renewing optimism and directions in the quest for optimized MET-targeting personalized cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.